Cargando…

The Development, Implementation, and Evaluation of a Pharmacist-Managed Therapeutic Drug Monitoring (TDM) Service for Vancomycin—A Pilot Study

Background: In recent years, pharmacists in Australia have been able to expand their scope to include the provision of a range of services. Although evidence has demonstrated the benefits of pharmacist-managed TDM services, recent studies have shown that these services are not prominent within Austr...

Descripción completa

Detalles Bibliográficos
Autores principales: Firman, Paul, Tan, Ken-Soon, Clavarino, Alexandra, Taing, Meng-Wong, Dixon, Sally, Singh, Helender, Whitfield, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785066/
https://www.ncbi.nlm.nih.gov/pubmed/36548329
http://dx.doi.org/10.3390/pharmacy10060173
_version_ 1784857962348544000
author Firman, Paul
Tan, Ken-Soon
Clavarino, Alexandra
Taing, Meng-Wong
Dixon, Sally
Singh, Helender
Whitfield, Karen
author_facet Firman, Paul
Tan, Ken-Soon
Clavarino, Alexandra
Taing, Meng-Wong
Dixon, Sally
Singh, Helender
Whitfield, Karen
author_sort Firman, Paul
collection PubMed
description Background: In recent years, pharmacists in Australia have been able to expand their scope to include the provision of a range of services. Although evidence has demonstrated the benefits of pharmacist-managed TDM services, recent studies have shown that these services are not prominent within Australia and that the current TDM workflow may not be optimal. Methods: An interventional pilot study was conducted of a pharmacist-managed TDM program for vancomycin at a tertiary hospital in Australia. Results: In total, 15 pharmacists participated in the program. They performed 50.5% of the medication-related pathology over the intervention period. Pharmacist involvement in the TDM process was more likely to lead to appropriate TDM sample collection (OR 87.1; 95% CI = 11.5, 661.1) and to an appropriate dose adjustment (OR 19.1; 95% CI = 1.7, 213.5). Pharmacists demonstrated increased confidence after the education and credentialling package was provided. Conclusions: This study demonstrated that a credentialling package for pharmacists can improve knowledge, skills, and confidence around the provision of pharmacist-managed TDM services for vancomycin. This may lead to the evolution of different roles and workflows enabling pharmacists to contribute more efficiently to improving medication safety and use.
format Online
Article
Text
id pubmed-9785066
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97850662022-12-24 The Development, Implementation, and Evaluation of a Pharmacist-Managed Therapeutic Drug Monitoring (TDM) Service for Vancomycin—A Pilot Study Firman, Paul Tan, Ken-Soon Clavarino, Alexandra Taing, Meng-Wong Dixon, Sally Singh, Helender Whitfield, Karen Pharmacy (Basel) Article Background: In recent years, pharmacists in Australia have been able to expand their scope to include the provision of a range of services. Although evidence has demonstrated the benefits of pharmacist-managed TDM services, recent studies have shown that these services are not prominent within Australia and that the current TDM workflow may not be optimal. Methods: An interventional pilot study was conducted of a pharmacist-managed TDM program for vancomycin at a tertiary hospital in Australia. Results: In total, 15 pharmacists participated in the program. They performed 50.5% of the medication-related pathology over the intervention period. Pharmacist involvement in the TDM process was more likely to lead to appropriate TDM sample collection (OR 87.1; 95% CI = 11.5, 661.1) and to an appropriate dose adjustment (OR 19.1; 95% CI = 1.7, 213.5). Pharmacists demonstrated increased confidence after the education and credentialling package was provided. Conclusions: This study demonstrated that a credentialling package for pharmacists can improve knowledge, skills, and confidence around the provision of pharmacist-managed TDM services for vancomycin. This may lead to the evolution of different roles and workflows enabling pharmacists to contribute more efficiently to improving medication safety and use. MDPI 2022-12-12 /pmc/articles/PMC9785066/ /pubmed/36548329 http://dx.doi.org/10.3390/pharmacy10060173 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Firman, Paul
Tan, Ken-Soon
Clavarino, Alexandra
Taing, Meng-Wong
Dixon, Sally
Singh, Helender
Whitfield, Karen
The Development, Implementation, and Evaluation of a Pharmacist-Managed Therapeutic Drug Monitoring (TDM) Service for Vancomycin—A Pilot Study
title The Development, Implementation, and Evaluation of a Pharmacist-Managed Therapeutic Drug Monitoring (TDM) Service for Vancomycin—A Pilot Study
title_full The Development, Implementation, and Evaluation of a Pharmacist-Managed Therapeutic Drug Monitoring (TDM) Service for Vancomycin—A Pilot Study
title_fullStr The Development, Implementation, and Evaluation of a Pharmacist-Managed Therapeutic Drug Monitoring (TDM) Service for Vancomycin—A Pilot Study
title_full_unstemmed The Development, Implementation, and Evaluation of a Pharmacist-Managed Therapeutic Drug Monitoring (TDM) Service for Vancomycin—A Pilot Study
title_short The Development, Implementation, and Evaluation of a Pharmacist-Managed Therapeutic Drug Monitoring (TDM) Service for Vancomycin—A Pilot Study
title_sort development, implementation, and evaluation of a pharmacist-managed therapeutic drug monitoring (tdm) service for vancomycin—a pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785066/
https://www.ncbi.nlm.nih.gov/pubmed/36548329
http://dx.doi.org/10.3390/pharmacy10060173
work_keys_str_mv AT firmanpaul thedevelopmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT tankensoon thedevelopmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT clavarinoalexandra thedevelopmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT taingmengwong thedevelopmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT dixonsally thedevelopmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT singhhelender thedevelopmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT whitfieldkaren thedevelopmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT firmanpaul developmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT tankensoon developmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT clavarinoalexandra developmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT taingmengwong developmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT dixonsally developmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT singhhelender developmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy
AT whitfieldkaren developmentimplementationandevaluationofapharmacistmanagedtherapeuticdrugmonitoringtdmserviceforvancomycinapilotstudy